CSF1R and breast carcinoma: While results from trials testing combined targeting of PD-1/LI and CSF-1R are still pending [37], promising efficacy signals of CSF-1R inhibitors have been demonstrated in combination with chemotherapy in solid organ malignancies, including breast cancer [77].